Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

NCT00532207 | Completed Phase 3

• 2 other identifiers: 8736B3D-MW-GHCR
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

To see if using teriparatide for 12 months will increase Bone Mineral Density at the lumbar spine in postmenopausal women with osteoporosis

Conditions

Osteoporosis, Post-Menopausal

Outcome Measures

Primary Outcomes (1)

• To test the hypothesis that therapy for 12 months with once daily subcutaneous PTH 1-34 (teriparatide; TPTD) 20 micrograms will increase Bone Mineral Density (BMD) at the lumbar spine in postmenopausal women with osteoporosis

Secondary Outcomes (6)

• To test the hypothesis that therapy for 3 months with once daily subcutaneous teriparatide 20 micrograms will increase markers of bone formation (P1NP, BSAP) and bone resorption (serum CTX) in postmenopausal women with osteoporosis

• To test the hypothesis that therapy for 12 months with once daily subcutaneous teriparatide 20 micrograms will increase markers of bone formation (P1NP, BSAP) and bone resorption (serum CTX) in postmenopausal women with osteoporosis.

• To evaluate safety of once daily subcutaneous teriparatide 20 micrograms for 12 months.

• To evaluate effect of teriparatide on changing in femoral neck and total hip BMD

• To test the hypothesis that treatment with TPTD will favorably affect back pain within the natural course of the disease

Study Arms (1)

A

EXPERIMENTAL

Drug: teriparatide

Interventions

teriparatide DRUG

subcutaneous 20 micrograms

Also known as: LY333334

A

Eligibility Criteria

• Age: 55 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Are postmenopausal women at least 55 years old and at least 2 years postmenopausal at the time of entry into the trial, and who have given informed consent before entering the study and after being informed of the risks, medications, and procedures to be used in the study. In addition, women below the age of 60 years with indeterminate menopause due to premenopausal hysterectomy must have their postmenopausal status confirmed with a serum FSH level \> 30 IU/L.
• Posterior-anterior lumbar spine (L1-L4) BMD and/or femoral neck BMD measurement at least \< 2.5 standard deviation (SD) from the mean of healthy, pre-menopausal women.
• Results of lumbar BMD (L1-L4) measurement must be available. The initial lumbar spine assessment and the determination of the patient's eligibility for entry into the screening phase will be made by the individual investigator. If the L-1 vertebra cannot be analyzed due to artifact, vertebral fracture, osteophytes, or other abnormalities, that vertebra should be excluded from the analysis.
• Normal or clinically insignificant abnormal laboratory values (as defined by the investigator) including serum calcium, 25 hydroxyvitamin D levels and alkaline phosphatase.
• Willing to be trained on and use a pen type injection delivery system on a daily basis for 12 months.

You may not qualify if:

• Active liver disease - liver enzymes (ALT, AST) more than three times the upper normal range, or a bilirubin of \> 2.0 mg/dl, or clinical jaundice.
• Abnormal thyroid function not corrected by therapy. Normal thyroid function will be documented by a normal TSH during screening phase
• History of active nephrolithiasis or urolithiasis in the prior 2 years. Patients with any documented history of nephro- or urolithiasis must have had an appropriate imaging procedure within the prior 6 months, such as, an intravenous pyelography (IVP), supine radiograph of the kidney ureter bladder (KUB), or renal ultrasound, which must document the absence of stones
• History of malignant neoplasms within the prior 5 years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. If malignant neoplasm was ever diagnosed, patient must presently be free of disease.
• Current pharmacological treatment for osteoporosis, other than calcium and Vitamin D
• History of Paget's disease, renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis, hyperparathyroidism (uncorrected), and intestinal malabsorption

Sponsors & Collaborators

• Eli Lilly and Company: lead

Study Sites (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Moscow, Russia

Location

Related Links

• Lilly Clinical Trial Registry

MeSH Terms

Conditions

Osteoporosis, Postmenopausal

Interventions

Teriparatide

Condition Hierarchy (Ancestors)

Osteoporosis; Bone Diseases, Metabolic; Bone Diseases; Musculoskeletal Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Parathyroid Hormone; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins

Study Officials

• Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

  Eli Lilly and Company

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: September 18, 2007
• First Posted: September 20, 2007
• Study Start: November 1, 2003
• Study Completion: December 1, 2004
• Last Updated: September 20, 2007

Record last verified: 2007-09

Locations

RU (1)